Therapeutic trial of rigidity-akinesia in children using L-Dopa
Lombard, M.; Tardieu, G.
Revue Neurologique (Paris) 129(6): 369
1973
ISSN/ISBN: 0035-3787 PMID: 4603921 Document Number: 58131
Document emailed within 1 workday
Related Documents
Eisenlohr, J.J.; Gehlen, W. 1974: Long-term study on the anti-rigidity effect of L-dopa and a decarboxylase inhibitor (ro 8-0576) Münchener Medizinische Wochenschrift 116(28): 1353-1356Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Wardas, J. 2003: Synergistic effect of SCH 58261, an adenosine A2A receptor antagonist, and L-DOPA on the reserpine-induced muscle rigidity in rats Polish Journal of Pharmacology 55(2): 155-164
Silva, M.; Valdés, B.; Bravo, I.; Saitúa, M.T. 1971: Therapeutic trial of Bactrim in urinary infection in children Revista Chilena de Pediatria 42(7): 469-476
Kreitler, S.; Zigler, E.; Kreitler, H. 1990: Rigidity in mentally retarded and nonretarded children American Journal of Mental Retardation: Ajmr 94(5): 550-562
Holt, J.; Børresen, B. 1986: Enuresis nocturna in school children in Bodö. a therapeutic trial with a vasopressin analog: desmopressin and imipramine Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 106(8): 651-654
Desnuelle, C.; Serratrice, G.; N'guyen, V.K.; Richelme, C.; Pinsard, N. 1989: A therapeutic trial of mazindol versus placebo in Duchenne muscular dystrophy. a one-year follow-up study of 14 children Archives Francaises de Pediatrie 46(10): 759-765
Patel, A.B.; Dhande, L.A.; Rawat, M.S. 2005: Therapeutic evaluation of zinc and copper supplementation in acute diarrhea in children: double blind randomized trial Indian Pediatrics 42(5): 433-442
Irena, A.H.; Bahwere, P.; Owino, V.O.; Diop, E.I.; Bachmann, M.O.; Mbwili-Muleya, C.; Dibari, F.; Sadler, K.; Collins, S. 2015: Comparison of the effectiveness of a milk-free soy-maize-sorghum-based ready-to-use therapeutic food to standard ready-to-use therapeutic food with 25% milk in nutrition management of severely acutely malnourished Zambian children: an equivalence non-blinded cluster randomised controlled trial Maternal and Child Nutrition 11(Suppl 4): 105-119
De Divitiis, E.; Cerillo, A.; Tata, M.R.; Decina, A. 1973: Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results Acta Neurologica 28(2): 208-212
Hansson, C.; Rorsman, H.; Rosengren, E. 1981: Pronounced formation of 5-OH-dopa at enzymatic oxidation of DOPA in the presence of ascorbic acid Acta Dermato-Venereologica 61(2): 147-148
Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10
Bizzarri, B.Mattia.; Tortolini, S.; Rotelli, L.; Botta, G.; Saladino, R. 2015: Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity Current Medicinal Chemistry 22(36): 4138-4165
Deutsch, E. 1997: Therapeutic trial, clinical research and therapeutic freedom--legal boundaries Zeitschrift für Arztliche Fortbildung und Qualitatssicherung 91(7): 698-700; Discussion 701
Riley, P.A. 1999: The great DOPA mystery: the source and significance of DOPA in phase i melanogenesis Cellular and Molecular Biology 45(7): 951-960
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Blair, M.L.; Reid, I.A.; Ganong, W.F. 1977: Effect of L-dopa on plasma renin activity with and without inhibition of extracerebral dopa decarboxylase in dogs Journal of Pharmacology and Experimental Therapeutics 202(1): 209-215
Zabel, M. 1979: Ultrastructure of thyroid C cells following long-term administration of 1-DOPA or alpha-methyl-DOPA Acta Medica Polona 20(1): 53-54
Vasil'ev, V.N. 1980: Effect of a test with 0.1 g of L-DOPA on the dynamics of urinary excretion of catecholamines and DOPA in schizophrenic patients Voprosy Meditsinskoi Khimii 26(6): 782-786